IOBCF - Ion Beam Applications SA

Other OTC - Other OTC Delayed price. Currency in USD
16.65
0.00 (0.00%)
At close: 02:47PM EDT
Stock chart is not supported by your current browser
Previous close16.65
Open16.65
Bid0.00 x 0
Ask0.00 x 0
Day's range16.65 - 16.65
52-week range11.13 - 20.00
Volume750
Avg. volume115
Market cap485.704M
Beta (5Y monthly)0.67
PE ratio (TTM)79.29
EPS (TTM)0.21
Earnings dateN/A
Forward dividend & yield0.20 (1.20%)
Ex-dividend date29 Jun 2022
1y target estN/A
  • Globe Newswire

    IBA signs Binding Term Sheet with Medtechnica Ltd for two Proteus®ONE proton therapy solutions at the Tel Aviv Sourasky Medical Center in Israel

    Louvain-La-Neuve, Belgium, May 22, 2023 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a Binding Term Sheet with Medtechnica Ltd for the installation of two Proteus®ONE1 compact proton therapy solutions at the Sourasky Medical Center (Ichilov Hospital) in Tel Aviv, Israel. Sourasky Medical Center has been selected by the Israel

  • Globe Newswire

    IBA Business Update – First Quarter 2023

    Louvain-la-Neuve, Belgium, 17 May 2023 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its business update for the first quarter ending 31 March 2023. Group Overview Strong balance sheet maintained with EUR 103 million net cash positionContinued focus on delivering EUR 1.3 billion Group backlog, with close to 65 equipment projects under installation in 2023Investment plan on track with R&D and digital initiatives to ensure IBA maintains and

  • Globe Newswire

    IBA Reports Full Year 2022 Results

    ALL-TIME RECORD ORDER INTAKE AND BACKLOG IBA ANNOUNCES MID-TERM GUIDANCE Louvain-la-Neuve, Belgium, 23 March 2023 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its consolidated results for the 2022 financial year. (EUR 000)​FY 2022​FY 2021​Variance​Variance %​Proton Therapy​218 761​169 923​48 838​28.7%​Other Accelerators​88 538​90 715​-2 177​-2.4%​Dosimetry​53 971​52 326​1 645​3.1%​ Total Net Sales​361 270​312 964​48 467​15.4%​ REBITDA​21

  • Globe Newswire

    IBA is looking for 100 new collaborators in Belgium by June 2023

    Louvain-la-Neuve, Belgium, 14 March 2023 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology wants to hire 100 new employees during the first half of 2023. Among the actions undertaken to achieve this goal, the company is organizing a special recruitment evening, "Meet & Join IBA", in Louvain-la-Neuve on March 28. Interested parties are invited to register on the Forem website. For more than 35 years, IBA has been designing, producing, and marketing

  • Globe Newswire

    IBA - Regulated Information

    IBA SA – Regulated information January 25th, 2023 Publication made under article 15 of the law of May 2, 2007 relating to the disclosure of major holdings in issuers whose shares are admitted to trading on a regulated market and containing various provisions (Belgian Gazette 12.VI.2007 ) (hereinafter, the “Law”) Under this provision: "[...] the issuer publishes the total capital, the total number of securities conferring the right to vote and voting rights, as well as, by category, the number of

  • Globe Newswire

    IBA announces contract with Moffitt Cancer Center for a Proteus®ONE proton therapy solution in Florida, US

    Louvain-La-Neuve, Belgium, 10 January 2023 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announces that it has received the downpayment for a contract signed at the end of December 2022 with the H. Lee Moffitt Cancer Center and Research Institute Hospital (“Moffitt”) in Tampa, Florida, US, for the installation of its Proteus®ONE1 compact proton therapy system. As Florida’s only National Cancer Institute-designated comprehensive cancer ce

  • Globe Newswire

    IBA signs contract to install a fully integrated X-ray irradiation solution in France

    Significant contract win for IBA’s Industrial Solutions; first time the division has sold a complete irradiation solution Louvain-La-Neuve, Belgium, 22 December 2022 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announced that it has signed a contract to install a fully integrated X-ray irradiation solution at a customer’s new service center site in France. The solution includes an IBA Rhodotron®, a Beagle® process control system, a safe

  • Globe Newswire

    IBA Wins 10 Proton Therapy System Contract in Spain

    Louvain-La-Neuve, Belgium, 08 December 2022 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today confirms that it has signed a contract with the Spanish Ministry of Health to install ten proton therapy systems across Spain as part of a significant public tender. This follows the announcement in August that IBA had qualified as the only supplier of the tender. The total value of the contract to IBA is currently EUR 217 million, all taxes exclude

  • Globe Newswire

    IBA – Transparency Notification

    Louvain-la-Neuve, Belgium, December 07th 2022 Summary of the notification IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on December 05th 2022. In its notification, La Société Fédérale de Participations et d’Investissement (SF

  • Globe Newswire

    IBA Business Update – Third Quarter 2022

    Louvain-La-Neuve, Belgium, 17 November 2022 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announces its business update for the third quarter ending 30 September 2022. Group Overview Business operations continue to be strong, with good performance across all four business units Exceptional group order intake of EUR 260 million at 30 September for 2022 to date, compared to EUR 133 million for the first nine months of 2021, driven by stron

  • Globe Newswire

    IBA expands its activities in Sub-Saharan Africa and signs contract with Sweden Ghana Medical Centre for an IntegraLab® PLUS in Accra, Ghana

    New contract to provide broader access to diagnostics in emerging markets Louvain-La-Neuve, Belgium, October 13, 2022 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, today announces a new contract with Sweden Ghana Medical Centre (SGMC) for an IntegraLab® PLUS in Accra, Ghana. SGMC is a leading private cancer care center focused on providing the highest quality cancer t

  • Globe Newswire

    ElsMed, Novatec and IBA sign contract to install radiopharmaceutical production center in Georgia

    The center will be equipped with a Cyclone® KIUBE offering the highest production capacity with a PET cyclotron. Louvain-La-Neuve, Belgium, October 4, 2022 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, Novatec International and ElsMed Healthcare Solutions, the leading Israeli medical-technological company, announced today that they have signed a contract for the insta

  • Globe Newswire

    IBA and SCK CEN launch Pantera, a joint-venture to produce actinium-225

    Louvain-La-Neuve, Belgium, 22 September 2022 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, and the Belgian Nuclear Research Centre SCK CEN today announced the name of their joint-venture: Pantera SA/NV, which they believe will bring new hope for cancer patients. As indicated in the announcement of the R&D strategic partnership, this new company will aim to secure the large-scale production of actinium-225 (225Ac), one of the most promising alp

  • Globe Newswire

    NorthStar Medical Radioisotopes and IBA Sign Agreement for Two Additional Rhodotron® Electron Beam Accelerators for Commercial Production of Radioisotopes

    NorthStar is further expanding commercial-scale domestic radioisotope production capabilities using IBA’s environmentally preferable Rhodotron® accelerator technology Louvain-La-Neuve, Belgium, and BELOIT, Wisconsin, USA September 20, 2022 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, and NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imagin

  • Globe Newswire

    IBA Reports Half Year 2022 Results

    RECORD ORDER INTAKE AND BACKLOG ACROSS THE GROUP HIGHLY ACTIVE PIPELINE FOR ALL BUSINESS LINES SOLID BALANCE SHEET WITH RECORD EUR 137 MILLION NET CASH Louvain-la-Neuve, Belgium, 31 August 2022 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its consolidated results for the first half of 2022. (EUR 000)H1 2022H1 2021VarianceVariance % Total Net Sales160 032137 18322 84916.7% Proton Therapy103 02670 47332 55346.2% Other Accelerators30 11040

  • Globe Newswire

    IBA and ScandiDos form strategic alliance to increase access to safe radiotherapy

    Louvain-la-Neuve, Belgium, Stockholm, Sweden, Aug. 30, 2022 - IBA S.A. (IBAB.BR), the leader in particle accelerator technology and a leader in dosimetry quality assurance solutions, and ScandiDos A.B. (SDOS.ST), a technology leader in advanced Radiation Therapy Quality Assurance, announced today that they have formed a strategic alliance for radiation therapy dosimetry solutions. The collaboration will enable the two businesses to work together on product development, marketing and product dist

  • Globe Newswire

    IBA qualifies as the only supplier for second round of tender to provide ten proton therapy units across Spain

    Louvain-La-Neuve, Belgium, 26 August, 2022 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces that the Company is the only proton therapy equipment supplier that has qualified for the second round of a significant public tender launched by the Spanish Ministry of Health. This public tender is aimed at selecting one or several proton therapy supp

  • Globe Newswire

    IBA, Fred Hutchinson Cancer Center and the University of Washington engage in a bench-to-bedside research program for FLASH Proton Therapy

    Louvain-la-Neuve, Belgium, August 2, 2022, IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, Fred Hutchinson Cancer Center and the University of Washington (UW), Seattle, announced a multi-year research collaboration today on ConformalFLASH®1 Proton Therapy. Under this collaboration, IBA will equip the proton therapy system and the proton gantry treatment room at the Fred Hutchinson Cancer Center with ConformalFLASH® research functionality, which wi

  • Globe Newswire

    IBA signs contract with Istituto Clinico Humanitas for a Proteus®ONE proton therapy solution in Italy

    Louvain-La-Neuve, Belgium, June 30, 2022 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a contract with Istituto Clinico Humanitas (Humanitas Research Hospital) for the installation of a Proteus®ONE1 compact proton therapy solution in Rozzano (Milan), Italy. IBA will start to recognize the revenue of this contract in 2022. The